TY - JOUR
T1 - RadioTransNet
T2 - Preclinical research network coordinated at the SFRO and SFPM
AU - Maingon, P.
AU - Marchesi, V.
AU - Azria, D.
AU - Balosso, J.
AU - Deutsch,
AU - Cohen Jonathan-Moyal, Jonathan-Moyal
AU - Giraud, P.
AU - Bayart,
N1 - Publisher Copyright:
© 2021 Société française de radiothérapie oncologique (SFRO)
PY - 2022/2/1
Y1 - 2022/2/1
N2 - The RadioTransNet programme launched under the auspices of French societies for radiation oncology (SFRO) and medical physics (SFPM) was approved by the French national cancer institute (INCa) in December 2018 and is dedicated to proposing a relevant national and transversal structure for preclinical research including translational research in radiation oncology with well-defined priority areas of research. Its activities, coordinated by a scientific committee that includes radiation oncologists, medical physicists, academic biologists, are structured around several main areas, i.e.: target volume definition, interaction of radiation with normal tissues, combined treatments and modern dose calculation approaches. Four work packages have been created in these areas and are associated with other objectives pertaining to fundamental radiobiology, early implementation of new drugs in a preclinical setting, contribution of imaging in this task, research in medical physics including transversal components such as medical oncology, radiology, nuclear medicine and also cost/efficiency evaluation. All these tasks will be included in a national network that uses the complementary expertise provided by partners involved in the scheme. Calls for proposals will be selected by the scientific council to be submitted to INCa and the various academic associations to obtain funding for the human and technical resources required to conduct under optimal conditions projects in preclinical and translational research in radiation-oncology.
AB - The RadioTransNet programme launched under the auspices of French societies for radiation oncology (SFRO) and medical physics (SFPM) was approved by the French national cancer institute (INCa) in December 2018 and is dedicated to proposing a relevant national and transversal structure for preclinical research including translational research in radiation oncology with well-defined priority areas of research. Its activities, coordinated by a scientific committee that includes radiation oncologists, medical physicists, academic biologists, are structured around several main areas, i.e.: target volume definition, interaction of radiation with normal tissues, combined treatments and modern dose calculation approaches. Four work packages have been created in these areas and are associated with other objectives pertaining to fundamental radiobiology, early implementation of new drugs in a preclinical setting, contribution of imaging in this task, research in medical physics including transversal components such as medical oncology, radiology, nuclear medicine and also cost/efficiency evaluation. All these tasks will be included in a national network that uses the complementary expertise provided by partners involved in the scheme. Calls for proposals will be selected by the scientific council to be submitted to INCa and the various academic associations to obtain funding for the human and technical resources required to conduct under optimal conditions projects in preclinical and translational research in radiation-oncology.
KW - Combined modality treatment
KW - Dose calculation
KW - French society for radiation oncology
KW - Guidelines
KW - Medical physics
KW - Normal tissues
KW - Preclinical research
KW - Radiobiology
KW - Radiotherapy
KW - Target volume
UR - http://www.scopus.com/inward/record.url?scp=85124222536&partnerID=8YFLogxK
U2 - 10.1016/j.canrad.2021.08.003
DO - 10.1016/j.canrad.2021.08.003
M3 - Article
C2 - 34862132
AN - SCOPUS:85124222536
SN - 1278-3218
VL - 26
SP - 108
EP - 115
JO - Cancer/Radiotherapie
JF - Cancer/Radiotherapie
IS - 1-2
ER -